DNA cleavage of novel propargylic sulfones. Enhancement of potency via intercalating interaction

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 10, 1996, Pages 1093-1098

  Dai, Wei Min ^a   Fong, Kin Chiu ^a   Danjo, Hiroshi ^b   Nishimoto, Sei Ichi ^b   Solow, Michael ^a   Mak, Wing Leung ^a   Yeung, Mau Lam ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLENE DERIVATIVE; ANTINEOPLASTIC AGENT; DNA; DOUBLE STRANDED DNA; FLUOROURACIL; INTERCALATING AGENT; LEXITROPSIN; NUCLEIC ACID BASE; SINGLE STRANDED DNA; SULFONE DERIVATIVE; TETRYLAMMONIUM;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA ALKYLATION; DNA CLEAVAGE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DNA INTERACTION; DRUG POTENCY; DRUG SYNTHESIS; ELECTROPHORESIS; HUMAN; HUMAN CELL;

EID: 0342854207     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00177-1     Document Type: Article

References (34)

1. (a) Molecular Aspects of Anticancer Drug-DNA Interactions; Neidle, S.; Waring, M. J. Eds.; CRC Press Inc.: Boca Raton, 1993; Vol. 1.
2. (b) Nicolaou, K. C.; Dai, W.-M. Angew. Chem. Int. Ed. Engl. 1991, 30, 1387.
3. (a) Nicolaou, K. C.; Skokotas, G.; Maligres, P.; Zuccarello, G.; Schweiger, E. J.; Toshima, K.; Wendeborn, S. Angew. Chem. Int. Ed. Engl. 1989, 28, 1272.
4. (b) Nicolaou, K. C.; Wendeborn, S.; Maligres, P.; Isshiki, K.; Zein, N.; Ellestad, G. Angew. Chem. Int. Ed. Engl. 1991, 30, 418.
5. Also see: (c) Kerwin, S. M. Tetrahedron Lett. 1994, 35, 1023.
6. (d) Wu, M.-J.; Lin, C-F.; Wu, J.-S.; Chen, H.-T. Tetrahedron Lett. 1994, 35, 1879.
7. (e) Sakai, Y.; Bando, Y.; Shishido, K.; Shibuya, M. Tetrahedron Lett. 1992, 33, 957.
8. (f) Basak, A.; Khamrai, U. K. Tetrahedron Lett. 1995, 36, 7913.
9. Xie, G.; Morgan, A. R.; Lown, J. W. BioMed. Chem. Lett. 1993, 3, 1565.
10. Dai, W.-M.; Fong, K. C. Tetrahedron Lett. 1995, 36, 5613.
11. (a) Pindur, U.; Haber, M.; Sattler, K. J. Chem. Edu. 1993, 70, 263.
12. (b) Bailly, C.; Henichart, J.-P. Bioconjugate Chem. 1991, 2, 379.
13. (c) Adam, W.; Cadet, J.; Dall'Acqua, F.; Epe, B.; Ramaiah, D.; Saha-Möller, C. R. Angew. Chem. Int. Ed. Engl. 1995, 34, 107.
14. (d) Denny, W. A. In Cancer Chemotherapeutic Agents; Foye, W. O. Ed.; American Chemical Society: Washington, DC, 1995; pp. 218-234.
15. (a) Pelton, J. G.; Wemmer, D. E. J. Am. Chem. Soc. 1990, 112, 1393.
16. (b) Bregant, T. M.; Groppe, J.; Little, R. D. J. Am. Chem. Soc. 1994, 116, 3635.
17. (c) Mrksich, M.; Dervan, P. B. J. Am. Chem. Soc. 1995, 117, 3325.
18. (d) Kigoshi, H.; Niwa, M.; Ohashi, H.; Tanaka, H.; Hirokawa, J.; Ishiwata, H.; Yamada, K. Tetrahedron Lett. 1995, 36, 5349.
19. (e) Rao, K. E.; Zimmermann, J.; Lown, J. W. J. Org. Chem. 1991, 56, 786.
20. (f) Bailly, C.; Sun, J.-S.; Colson, P.; Houssier, C.; Hélène, C.; Waring, M. J.; Hénichart, J.-P. Bioconjugate Chem. 1992, 3, 100.
21. (g) Nielsen, P. E. Bioconjugate Chem. 1991, 2, 1.
22. (h) Geierstanger, B. H.; Mrksich, M.; Dervan, P. B.; Wemmer, D. E. Science 1994, 266, 646.
23. (i) Cory, M. In Cancer Chemotherapeutic Agents; Foye, W. O. Ed.; American Chemical Society: Washington, DC, 1995; pp. 311-344.
24. (a) Griffin, J. H.; Dervan, P. B.; J. Am. Chem. Soc. 1987, 109, 6840.
25. (b) Fukuda, R.; Takenaka, S.; Takagi, M. J. Chem. Soc., Chem. Commun. 1990, 1028.
26. Paloma, L. G.; Smith, J. A.; Chazin, W. J.; Nicolaou, K. C. J. Am. Chem. Soc. 1994, 116, 3697.
27. Pourcelot, G.; Cadiot, P.; Willemart, A. C. R. Hebd. Seances Acad. Sci. 1961, 252, 1630.
28. 13C NMR spectra and MS data.
29. Lown, J. W. The Chemistry of DNA Damage by Antitumor Drugs. In Molecular Aspects of Anticancer Drug Action; Neidle, S.; Waring M. J. Eds.; Verlag Chemie: Weinheim, 1983; pp. 283-314.
30. The DNA substrate was treated with 50 μM ethidium bromide for 2 h before incubating with the propargylic sulfones.
31. In contrast to the naphthalene-derived propargylic sulfone 10, incubation of the anthryl analogs 11 and 12 (1 mM) with the EB-pretreated DNA (50 μM) at 37 °C for 72 h or 192 h under the conditions indicated in Figure 4 showed a complete loss of DNA cleavage activity. It gives a qualitative order of intercalating ability with DNA: naphthalene = ethidium bromide > anthracene.
32. Kohn K. W. Biological Aspects of DNA Damage by Crosslinking Agents. In Molecular Aspects of Anticancer Drug Action; Neidle, S.; Waring M. J. Eds.; Verlag Chemie: Weinheim, 1983; pp. 315-361.
33. (a) Woo, J.; Sigurdsson, S. T.; Hopkins, P. B. J. Am. Chem. Soc. 1993, 115, 3407.
34. (b) Rink, S. M.; Solomon, M. S.; Taylor, M. J.; Rajur, S. B.; McLaughlin, L. W.; Hopkins, P. B. J. Am. Chem. Soc. 1993, 115, 2551.